Vascular endothelial growth factor in node-positive breast cancer patients treated with adjuvant tamoxifen

In 212 postmenopausal women with node-positive oestrogen receptor-positive (ER(LBA)) breast cancer subjected to radical surgery and adjuvant tamoxifen, the risk of 6-year relapse increased with increasing values of intratumoral vascular endothelial growth factor (VEGF) in patients whose tumours had...

Descripción completa

Detalles Bibliográficos
Autores principales: Coradini, D, Biganzoli, E, Pellizzaro, C, Veneroni, S, Oriana, S, Ambrogi, F, Erdas, R, Boracchi, P, Daidone, M G, Marubini, E
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Molecular and Cellular Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394273/
https://www.ncbi.nlm.nih.gov/pubmed/12865915
http://dx.doi.org/10.1038/sj.bjc.6601060
Descripción
Sumario:In 212 postmenopausal women with node-positive oestrogen receptor-positive (ER(LBA)) breast cancer subjected to radical surgery and adjuvant tamoxifen, the risk of 6-year relapse increased with increasing values of intratumoral vascular endothelial growth factor (VEGF) in patients whose tumours had a low/intermediate ER(LBA) content compared to patients with high-ER(LBA) tumours. These findings indicate that tumour progression, activated or sustained by high VEGF levels, may be counteracted in high-ER(LBA) cancers by tamoxifen, which in contrast fails to contrast the metastatic potential in low-ER(LBA) tumours.

Ejemplares similares